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Topical dura mater application of CFA
induces enhanced expression of c-fos and
glutamate in rat trigeminal nucleus
caudalis: attenuated by KYNA derivate
(SZR72)
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Abstract
Background: Migraine is a debilitating neurological disorder where trigeminovascular activation plays a key role.
We have previously reported that local application of Complete Freund’s Adjuvant (CFA) onto the dura mater
caused activation in rat trigeminal ganglion (TG) which was abolished by a systemic administration of kynurenic
acid (KYNA) derivate (SZR72). Here, we hypothesize that this activation may extend to the trigeminal complex in the
brainstem and is attenuated by treatment with SZR72.
Methods: Activation in the trigeminal nucleus caudalis (TNC) and the trigeminal tract (Sp5) was achieved by
application of CFA onto the dural parietal surface. SZR72 was given intraperitoneally (i.p.), one dose prior CFA
deposition and repeatedly daily for 7 days. Immunohistochemical studies were performed for mapping glutamate,
c-fos, PACAP, substance P, IL-6, IL-1β and TNFα in the TNC/Sp5 and other regions of the brainstem and at the C1-C2
regions of the spinal cord.
Results: We found that CFA increased c-fos and glutamate immunoreactivity in TNC and C1-C2 neurons. This effect
was mitigated by SZR72. PACAP positive fibers were detected in the fasciculus cuneatus and gracilis. Substance P,
TNFα, IL-6 and IL-1β immunopositivity were detected in fibers of Sp5 and neither of these molecules showed any
change in immunoreactivity following CFA administration.
Conclusion: This is the first study demonstrating that dural application of CFA increases the expression of c-fos and
glutamate in TNC neurons. Treatment with the KYNA analogue prevented this expression.
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Background
Migraine is among the leading causes of disability,
having a huge impact on public health [1, 2]. Studies
show that each year 2.5% of episodic migraine disease con-
verts into chronic migraine [3] which appears as a distinct
entity in the classification of the International Headache
Society. Although numerous studies have been performed
aiming to understand the pathophysiology of migraine and
the chronification process, however this is still enigmatic.
The trigeminal system plays a pivotal role in the genesis of
migraine headache [4, 5]. The pseudo-unipolar nerve cells
of the trigeminal ganglion (TG), provide sensory innerv-
ation of cranial structures and meningeal vessels while
central projections terminate in trigeminal nucleus caudalis
(TNC) and C1-C2 region of the spinal cord [6]. This
trigeminovascular complex transmits pain signals from
meningeal and cerebral vessels to the brainstem and
second-order neurons terminate in the thalamus and cor-
tical regions, where further transmission and modulation of
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pain sensation occur [6–8]. Following continous and re-
peated stimulation peripheral and central sensitisation of
the primary-neurons might occur, leading to reduced acti-
vation treshold, represented clinically by allodynia [4, 9, 10].
Previous studies have shown that application of inflam-
matory substances on the dura mater causes central sensi-
tisation of the neurons in TNC and at C1-C2 levels of the
spinal cord [6, 10, 11]. Recent studies have demonstrated
lower levels of kynurenic acid (KYNA) in serum of pa-
tients suffering from chronic migraine compared to con-
trols [12, 13]. KYNA could be a new therapeutic line in
migraine chronification, but KYNA can poorly cross the
blood–brain barrier (BBB), while newer KYNA analogues
have better BBB penetration characteristics [14, 15]. We
have recently developed an animal model for long-term
trigeminovascular activation following application of
Complete Freund’s Adjuvant (CFA) onto the surface of
the dura mater [16]. We found activation of satellite glial
cells and neurons of the trigeminal ganglion (IL-1,
pERK1/2) that were abolished by the KYNA-analogue,
SZR72 [17] possibly acting on peripheral and central
gluatamate receptors (30). The present study was designed
to examine whether dural application of CFA can cause
activation of the central part of the trigeminalvascular
system,: the TNC and C1-C2 regions of the spinal cord.
We asked the question whether the CFA-induced activa-
tion might be mitigated by use of SZR72 intraperitoneally.
Methods
Synthesis of novel KYNA derivative
The KYNA amide reported here was designed in the
Pharmaceutical Chemistry and Research Group for Stereo-
chemistry, University of Szeged Hungary. The synthesis pro-
cedure has previously been presented [15, 17]. The KYNA
analogue (SZR72, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride) has the following
structural properties: the presence of a water-soluble side-
chain, the inclusion of a new cationic centre, and side-chain
substitution in order to enhance brain penetration [17].
Animals
Adult male Sprague–Dawley rats (220–300 g) (n = 30)
were used. The animals were raised and maintained
under standard laboratory conditions with free access to
food and tap water. The study followed the guidelines of
the European Communities Council (86/609/ECC) and
was approved by the Ethics Committee of The Faculty of
Medicine, University of Szeged, Hungary (I-74-12/2012).
Treatments
The animals were divided into 7 groups: (i) CFA + saline
application to the dura, (ii) saline application to the dura,
(iii) pre-treatment KYNA (KYNA analog, 300 mg/kg
body weight dissolved in 1 ml saline, 1 h before CFA
administration), (iv) pre-treatment saline (saline, 1, ml 1 h
before CFA), (v) repeated treatment (KYNA analog,
300 mg/kg body weight dissolved in 1 ml saline every 12 h,
for 7 days), (vi) repeated saline (saline 1 ml every 12 h, for
7 days) and (vii) fresh (intact, control rats) (Table 1).
Operation
The operation has been described in details earlier
[16, 17]. Briefly, animals were deeply anesthetized and
a handheld drill was used to remove a 3x3 mm large
portion of the parietal bone, cooled by saline irrigation to
avoid local healing. The hole was made postero-laterally
to the bregma (5 mm), on the left side, care being taken
not to penetrate the dura mater. Ten μl of CFA (Sigma-
Aldrich, St. Louis, MO, USA) or saline was applied on the
dural surface, and washed with saline after 20 min.
Both treated and control animals were transcardially
fixation-perfused with 4% paraformaldehyde in buffer
after 7 days. As fresh control, intact rats were used.
Tissue analysis
After the perfusion-fixation the TNC brainstem region and
C1-C2 region of the spinal cord were removed (−1, +5 mm
from the obex). Specimens were frozen on dry ice, stored at
−80 °C and prepeared for immunohistochemistry. To en-
compass TNC, sections were collected from 6 different levels
from the central canal was visualized to the C1 segment of
the spinal cord. (100–120 sections in total per animal).
Immunohistochemistry and microscopic analysis
Immunohistochemical staining was performed to dem-
onstrate the localization of glutamate, c-fos, TNF-α, IL-
1β, IL-6, substance P and PACAP. Details of the primary
and secondary antibodies are given in Table 2 and 3.
The immunohistochemical method and the microscopic
analysis have been described earlier [16]. The areas of the
brainstem were identified using rat brain atlas (Paxinos
and Watson, second edition, 1986). Each procedure was
repeated a minimum of three times to validate the results







CFA CFA - - 6
Saline saline - - 3
CFA + KYNA
pre-treatment
CFA KYNA - 6
CFA + saline
pre-treatment
CFA saline - 3
CFA + KYNA repeated CFA KYNA KYNA 6
CFA + saline repeated CFA saline saline 3
Fresh, control
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- - - 3
Lukács et al. The Journal of Headache and Pain  (2017) 18:39 Page 2 of 8
and minimize any experimental errors using the same
antibody stock. Negative controls were performed for each
set by omitting the primary antibody. One examinator was
blinded. Any resulting immunofluorescence would suggest




In intact (fresh) animals, glutamate immunoreactivity (GI)
was detected in fibers of the trigeminal tract on every level
of the TNC (Fig. 1a and b). A few homogeneously stained
glial cells could also be found. The staining also displayed
some homogenously labelled neurons, especially in TNC
in the caudal part of the brainstem.
Application of CFA on the dura (group CFA 7days),
similar staining pattern was observed, with an obvious
increase in the intensity and amount of glutamate posi-
tive neurons in the TNC (Fig. 1). In the gelatinous layer
a clearly increased intensity could be seen. With higher
magnification, cells with intensely stained cytoplasm
were identified in this region (Fig. 1). The aspect is
specific to the medial part of the spinal trigeminal nu-
cleus: triangular or multipolar shaped, medium-sized
cells with an irregular arrangement. No difference in the
fiber staining was noted. In the application of saline
group, the same GI pattern was observed (Fig. 1).
In group pretreated with SZR72, the increased expres-
sion was abolished. The intensity and number of glutam-
ate immunoreactive cells remained at the level observed
in healthy, intact animals. No clear difference could be vi-
sualized between pre-treatment and repeated-treatment of
KYNA, and no difference was noted in the fibers and glial
cells. In the application of saline group, the same GI pat-
tern was observed as in fresh control (Fig. 1).
On the level of the C1-C2 region of the spinal cord GI
was found in the anterior and dorsal horns (lamina I,
lamina II) and the areas surrounding the central canal.
In these areas no difference was found between the dif-
ferent groups (no cells, only fibers). A summary of these
results is presented in Table 4.
C-fos
In intact (fresh) rats, few c-fos positive neuronal nuclei,
but no nucleolei, were observed in the caudal part of the
spinal trigeminal nucleus (Sp5C, TNC); these were mainly
seen in the gelatinous layer (Fig. 2). No difference could
be observed between cranial and caudal levels of the TNC.
After application of CFA onto the dura mater, an in-
crease in the number of c-fos positve nuclei could be de-
tected, especially in the caudal areas of the TNC, close to
the spinal cord (Fig. 2). No increased immunoreactivity
was visualised using saline application on the dura (Fig. 2).
Administration of SZR72 reduced the CFA-induced
activation in neuronal nuclei at every level of the TNC,
similar to the low expression seen in fresh rats. No
significant difference could be shown between the pre-
treatment and repeated-treatment of SZR72. After
treatment with saline, we noted no increase in the c-fos
expression, showing that treatment with saline did not
have effect on the CFA-induced TNC activation (Fig. 2i).
The results of the c-fos immunostaining are summa-
rized in Table 5.
PACAP
PACAP immunoreactivity was found in fibers of the tri-
geminal tract, both in healthy and CFA inflammation-
induced animals. PACAP immunoreactivity was found in
the brainstem, in the spinal cord, especially in the large
neurons of the anterior horn, in the dorsal horn, around
the central canal and the ependymal cells of the central
canal. PACAP immunoreactive fibers were observed in al-
most every tract in the spinal cord (dorsal corticocerebel-
lar tract, spinocerebellar tracts, medial longitudinal tract,
pyramidal tract). In these territories no difference was de-
tected between different groups (SZR 72 had no effect).
Table 2 Details of primary antibodies used for
immunohistochemistry
Name Product code Host Dilution Company
Anti c-fos PC38 Rabbit 1:100 Merck Millipore,
Darmstadt,
Germany
Anti PACAP-38 B57–1 Rabbit 1:100 Europroxima,
Arnhem,
Netherlands
Anti Glutamate G9282 Mouse 1:100 Sigma-Aldrich,
St-Luis,
MO, USA
Anti Glutamate AB5018 Rabbit 1:100 Merck Millipore,
Darmstadt,
Germany
Anti Substance P B 45–1 Rabbit 1:200 Europroxima,
Arnhem,
Netherlands
Anti IL-1β ab 9787 Rabbit 1:100 Abcam,
Cambridge, UK
Anti IL-6 ab6672 Rabbit 1:200 Abcam,
Cambridge, UK
Anti-TNF α ab66579 Rabbit 1:400 Abcam,
Cambridge, UK
Table 3 Details of secondary antibodies used for
immunohistochemistry
Conjugate and host Against Diluation Company
FITC (goat) anti-rabbit 1:100 Cayman Chemical,
Ann Arbor, MI, USA
Alexa 488 (goat) anti-mouse 1:100 Invitrogen, CA, USA
Alexa 594 (donkey) anti-rabbit 1:100 Jackson Immuno Research,
West Baltimor, PA, USA
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Substance P
Substance P immunoreactivity was limited to nerve fi-
bers of the spinal trigeminal tract and to the gelatinous
layer (Fig. 3). Some positive fibers, surrounding the
SP5C were also visualized. No difference was noted be-
tween different levels of TNC and a slight increased in-
tensity of the fiber staining could be detected after CFA
application, but not in the gelatinous layer.
TNF-α
TNF-immunoreactivity was found in the trigeminal tract,
with dense fiber staining in the spinal trigeminal tract, but
no glial or neuronal staining was detected at either level of
the TNC. In the spinal cord few, small sized neurons were
detected, especially around the central canal (Fig. 3). Some
TNF- α positive fibers were identified in other tracts of
the spinal cord (dorsal cortico-cerebellar tract, spino-
cerebellar tracts, medial longitudinal tract, pyramidal
tract). No difference was noted between the groups.
IL-6
IL-6 positivity was detected in the fibers and in the cyto-
plasm of some glial cells, showing a homogenous stain-
ing in the spinal trigeminal tract. Some homogeniously
stained neurons were detected in the TNC. In the spinal
cord, some positive neurons could be seen in the caudal
part of the spinal trigeminal nucleus, in the large neu-
rons of the anterior horn, in the dorsal horn and the
ependymal cells of the central canal (Fig. 3). Intensely
positive fibers were visualised in the cuneate and gracile
fasciculus. After application of CFA, similar staining pat-
terns as for the non-CFA groups were found.
IL-1β
IL-1β immunohistochemistry showed the same staining pat-
tern as for IL6 and TNFα, with no change after CFA induced
activation (Fig. 3). IL-1β immunoreactivity showed a granular
cytoplasmatic stainig, previously described in the TG (14).
Fig. 1 Glutamate immunoreactivity in the TNC. In case of fresh, intact animals a few homogenously stained neurons were detected in the TNC.
Following CFA application on the dura a clear increase in staining intensity and amount of glutamate positive cells can be seen. After saline
application on the dura a moderate increase was seen compared to fresh, intact animals. I.p. treatment with KYNA derivate abolished the amount
of glutamate positive cells following CFA induced activation, whereas i.p saline treatment had no effect on glutamate reactivity in the TNC. “+”
represent a light, “++” moderate, “+++” strong increase in immunoreactivity








Fresh -\+ ++ -\+
CFA 7d +++ ++ -\+
Saline 7d + ++ -\+
CFA+ SZR72 one dose -\+ ++ -\+
CFA+ SZR72 repeated -\+ ++ -\+
CFA+ saline one dose +++ ++ -\+
CFA + saline repeated +++ ++ -\+
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Discussion
In this study we present the immunostaining pattern of sev-
eral neuronal messengers and cytokines in the TNC/C1-C2
spinal region (11) that are indicated in migraine patho-
physiology. CFA is a potent immun- potentiator, used in
various peripheral pain model. (Spinal distribution of c-Fos
activated neurons expressing enkephalin in acute and
chronic pain models, 1st manu) We asked the question
whether application of CFA on a defined area of the dura
mater could cause activation of second-order neurons in
the TNC and whether this activation can be mitigated by
systemic adminstration of a KYNA analogue.
Gluatamate, the major excitatory neurotransmitter in
CNS plays a key role in the trigeminovascular activation,
especially in central sensitisation via activation of NMDA
receptors [18, 19]. Glutamate appears to be involved in
nociception since glutamate is expressed in the trigeminal
ganglion and other sensory ganglia [20, 21]. Glutamate can
be released from neurons following nociceptive stimuli pu-
tatively acting on satellite glial cells (SGC) [22] but is also
expressed in the sensory Aδ – fibers (19).
The kynurenine pathway, the major route of tryptophan
metabolism to nicotinamide, has an important role in sev-
eral diseases of the CNS [23–25]. Kynurenic acid (KYNA)
is one of the neuroactive metabolits of the kynurenine path-
way in human astrocytes [26] protecting against neuronal
cell-death [27]. KYNA in low concentration enhances
AMPA receptor activity [28, 29], while in high concen-
trations blocks the NR1 subunit of the NMDA receptors
[19, 30]. NMDA receptor consists of NR1, NR2 and NR3
subunits, where NR1 subunit has a glycine- binding do-
main. Glycine is essential for the functioning of the NMDA
receptor and KYNA acts as an antagonist on the gylcine-
binding site (NR1) (18). High level of KYNA might have a
neuroprotective effect and could act on glutamate recep-
tors, exerting an inhibitory effect on glutamate release [23].
Here we asked the question whether the KYNA analogue
might act on the fibers and cells in the TNC/C1-C2. Previous
work has shown a positive effect in TG following CFA injec-
tion into the temporomandibular joint [31] while SZR 72
decreased c-fos activation in the TNC in nitroglycerin
Fig. 2 C-fos immunoreactivity in the TNC. In case of fresh, intact rats few c-fos positive neuronal nuclei but no nucleolei could be observed. After
appilcation of CFA on t he dura mater large amount of c-fos positive nuclei was detected. Saline application on the dura mater caused no
increase in immunoreactivity compared to fresh, intact control. I.p. treatment with KYNA derivate was able to abolish the activation caused by
application of CFA on the dura. I.p. saline had no such effect. “+” represents a light, “++” moderate, “+++” strong increase in immunoreactivity






CFA + SZR72 one dose +
CFA+ SZR72 repeated +
CFA + saline +++
CFA + saline repeated +++
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induced trigeminal activation [32]. We have reported that
one dose of SZR 72 is able to reduce dura mater applied
CFA induced activation in the TG [16]. C-fos immunoreac-
tivity is a widely used marker of neuronal activity in the
TNC [33, 34]. In the present study we report increased c-fos
immunoreactivity following dura mater application of CFA
as a sign of neuronal activity of TNC neurons. This effect is
attenuated by SZR72. Glutamate activation as a sign of cen-
tral sensitization can be observed in the second-order neu-
rons after use of CFA, this effect that is also mitigated by the
KYNA analogue. Surprisingly repeated-treatment of SZR 72
was not seen to be more effective than pre-treatment with
one dose prior CFA application neither in the TG [16] nor
in the TNC. Therefore we postulate that early KYNA
derivate intervention can block the development of central
sensitization, whereas late, repeated treatment might
not be able to further moderate mechanisms of central
sensitization. Consequently, we assume that the action of
the KYNA analogue seems to be exerted on the periphery
that is conveyed to neurons of TNC, but an effect on central
mechanisms cannot be surely excluded. Further studies are
needed to elucidate the possible site of actions of the KYNA
derivate.
In this study we examine a fair number of molecules
suggested to play a role in migraine. Among these CGRP
and PACAP 38 (PACAP) is currently of particular inter-
est. CGRP plays an important role in migraine patho-
physiology and localization of CGRP and its receptors
(CLR and RAMP1) has already been described in TNC
and C1 region of the spinal cord [35, 36]. PACAP is a
neuromodulator that has some common actions with
CGRP, sharing the same receptors RAMP1 subunit [37].
PACAP might play a role in migraine having various
neurobiological functions such as inhibitory effect on
neurogenic inflammation [38]. PACAP has shown to be
involved in trigeminovascular activation as PACAP-38
Fig. 3 Summary of PACAP, Substance P, TNF-α, IL-6 and IL-1β immunoreactivity in the C1-C2 region of the spinal cord. PACAP immunoreactivity
was detected in the dorsal horn and in almost every tract of the spinal cord. Substance P immunoreactvity was limited to the fibers of the spinal
trigeminal tract. TNF-α immunopositivity was mainy seen in the small cells surrounding the central canal. IL-6 immunopositivity was shown in the
large neurons of the anterior horn and in nerve endings of these cells. IL-1 β immunopositvity was mainy seen in different tracts of the spinal
cord, few positive cells, with granular intracytoplasmatic staining were also detected
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infusion caused headache in healthy volunteers [39] and
PACAP-38-like immunoreactivity has proved to be
altered in ictal compared to interictal phase of migraine
and in cluster headache [40, 41]. It is suggested that the
effect of PACAP is biphasic: lower concentration
increasing, higher concentration inhibiting the NMDA
receptor activation [42]. We have found PACAP positive
but no change in TNC and C1-C2.
In addition, we examined several other molecules puta-
tively involved in migraine pathophysiology: SP, IL-1β, IL-6
and TNF-α which have all been shown to be associated
with activation of the trigeminovascular system [43–46].
While we could document their presesnce in the TNC and
C1-C2 of the spinal cord, we did not observe a difference in
expression between saline vehicle or CFA administration.
Conclusion
In conclusion, we report activation in neurons and fibers of
TNC and C1-C2 following application of CFA on the dura
mater that was mitigated by SZR 72. To our knowledge this
is the first study that presents the cellular distribution of
proinflammatory cytokines (IL-6, IL- 1β and TNF-α) in the
TNC and in the C1-C2 region of the spinal cord. This might
represent a further step in understanding the functional
neuroanatomy of the trigeminal pathway. We found in-
creased c-fos and glutamate immunoreactivity in the TNC
following application of CFA on the dura mater that was
abolished by the KYNA derivate. Further studies are needed
to explore the possible mechanisms involved, which could
result in a new therapeutic line in treatment of migraine.
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